Anti-C5 Antibody Blocks MAC Formation While Preserving C5a
Solution Overview
Problem
Current therapeutics targeting the formation of the membrane attack complex (MAC) in age-related macular degeneration (AMD) often block C5a formation, leading to unintended loss of functional C5a activity, which is crucial for tissue homeostasis and neural survival.
Innovation Solution
Development of a novel monoclonal anti-complement C5 antibody that binds to C5 but not C5a, allowing processing to C5a while inhibiting the formation of MAC, thereby preventing pathogenic MAC formation associated with AMD without affecting upstream supportive ocular tissues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If current therapeutics block C5a formation to inhibit MAC, then MAC formation is inhibited, but functional C5a activity is lost which is crucial for tissue homeostasis and neural survival
Solution Approach 1:
The invention segments the C5 protein into two distinct functional outcomes: C5a (anaphylatoxin) and C5b (MAC initiation). By developing antibodies that specifically target C5b while sparing C5a, the therapy selectively inhibits MAC formation while preserving C5a-mediated beneficial effects on tissue homeostasis and neural survival.
Solution Approach 2:
The patent introduces monoclonal antibodies as intermediary molecules that bind to specific epitopes on C5b, preventing MAC assembly without interfering with C5a generation. These antibodies act as mediators that selectively block the harmful MAC pathway while allowing the beneficial C5a pathway to proceed.
2Object-affected harmful factors
If C5 is completely inhibited to prevent MAC formation, then pathogenic MAC is blocked, but upstream supportive ocular tissues are also affected
Solution Approach 1:
The invention applies local quality by targeting specific regions (epitopes) on the C5b molecule that are critical for MAC assembly, while leaving other regions intact that are necessary for C5a generation and upstream ocular tissue support functions. This localized targeting achieves selective inhibition.
3Object-affected harmful factors
If non-specific C5 inhibition is used, then MAC formation is blocked, but specificity and precision of therapy is reduced
Solution Approach 1:
The patent extracts and targets only the specific C5b component responsible for MAC initiation, separating it from the C5a component that provides beneficial effects. This extraction approach enables precise targeting of MAC formation while preserving other C5 functions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibody effectively blocks MAC formation while preserving the beneficial activities of C5a, maintaining vision by reducing cellular damage and inflammation in AMD, thus offering a targeted therapeutic approach for AMD treatment.
Implementation Method 1
a novel monoclonal anti-complement C5 antibody that binds to C5 but not C5a
Implementation Method 2
inhibiting the formation of MAC (membrane attack complex)
Data Source
AI summary
The present disclosure relates to antibodies and polynucleotides encoding the same, that may be used to prevent, control, or reduce the activity of the complement pathway. In addition, the disclosure is directed to compositions and methods for diagnosing and treating diseases mediated by or involving complement C5. Specifically, the disclosure is related to C5 antibodies.